Trial Profile
Safety and Efficacy of Ustekinumab in the Treatment of Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary) ; Sodium chloride
- Indications Palmoplantar pustulosis
- Focus Registrational; Therapeutic Use
- 06 Aug 2012 Actual patient number amended from 40 to 433 as reported by ClinicalTrials.gov record.
- 06 Aug 2012 Actual end date (1 Nov 2011) added as reported by ClinicalTrials.gov record.
- 01 Nov 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.